SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hebert J. M.)
 

Search: WFRF:(Hebert J. M.) > (2010-2014) > Icatibant, a New Br...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005370naa a2200985 4500
001oai:lup.lub.lu.se:c47411d8-02ff-4eb4-8169-1470cf8f6fa4
003SwePub
008160401s2010 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/16778182 URI
024a https://doi.org/10.1056/NEJMoa09063932 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Cicardi, M.4 aut
2451 0a Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
264 1c 2010
520 a BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.)
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
700a Banerji, A.4 aut
700a Bracho, F.4 aut
700a Malbran, A.4 aut
700a Rosenkranz, B.4 aut
700a Riedl, M.4 aut
700a Bork, K.4 aut
700a Lumry, W.4 aut
700a Aberer, W.4 aut
700a Bier, H.4 aut
700a Bas, M.4 aut
700a Greve, J.4 aut
700a Hoffmann, T. K.4 aut
700a Farkas, H.4 aut
700a Reshef, A.4 aut
700a Ritchie, B.4 aut
700a Yang, W.4 aut
700a Grabbe, J.4 aut
700a Kivity, S.4 aut
700a Kreuz, W.4 aut
700a Levy, R. J.4 aut
700a Luger, T.4 aut
700a Obtulowicz, K.4 aut
700a Schmid-Grendelmeier, P.4 aut
700a Bull, C.4 aut
700a Sitkauskiene, B.4 aut
700a Smith, W. B.4 aut
700a Toubi, E.4 aut
700a Werner, Sonjau Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)lung-swe
700a Anne, S.4 aut
700a Bjorkander, J.4 aut
700a Bouillet, L.4 aut
700a Cillari, E.4 aut
700a Hurewitz, D.4 aut
700a Jacobson, K. W.4 aut
700a Katelaris, C. H.4 aut
700a Maurer, M.4 aut
700a Merk, H.4 aut
700a Bernstein, J. A.4 aut
700a Feighery, C.4 aut
700a Floccard, B.4 aut
700a Gleich, G.4 aut
700a Hebert, J.4 aut
700a Kaatz, M.4 aut
700a Keith, P.4 aut
700a Kirkpatrick, C. H.4 aut
700a Langton, D.4 aut
700a Martin, L.4 aut
700a Pichler, C.4 aut
700a Resnick, D.4 aut
700a Wombolt, D.4 aut
700a Fernandez Romero, D. S.4 aut
700a Zanichelli, A.4 aut
700a Arcoleo, F.4 aut
700a Knolle, J.4 aut
700a Kravec, I.4 aut
700a Dong, L.4 aut
700a Zimmermann, J.4 aut
700a Rosen, K.4 aut
700a Fan, W. -T.4 aut
710a Lungmedicin, allergologi och palliativ medicinb Sektion II4 org
773t New England Journal of Medicineg 363:6, s. 532-541q 363:6<532-541x 0028-4793
856u http://dx.doi.org/10.1056/NEJMoa0906393y FULLTEXT
8564 8u https://lup.lub.lu.se/record/1677818
8564 8u https://doi.org/10.1056/NEJMoa0906393

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view